Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial

Conclusions: Upfront combination therapy resulted in significant changes in hemodynamics, RV structure and function, and RV-pulmonary vascular coupling as well as functional status at 36 weeks of therapy. When compared to previous clinical trials, these data suggest initial combination therapy is very effective for SSc-PAH.

Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Hassoun, P., Zamanian, R., Damico, R., Khair, R., Kolb, T., Tedford, R., Hulm, O., Pisanello, C., Sato, T., Corona-Villalobos, C., Zimmerman, S., Gashouta, M., Minai, O., Torres, F., Chin, K., Girgis, R., Mathai, S. Tags: 4.3 Pulmonary Circulation and Pulmonary Vascular Disease Source Type: research